Fountain Health Insurance to cover Grail multicancer test

By LabPulse.com staff writers

June 22, 2022 -- Grail’s multicancer early detection (MCED) blood test, Galleri, is being made available to Fountain Health Insurance customers at 100% coverage, the firms announced on Tuesday.

In a clinical study, the Galleri test demonstrated that it detects a shared signal from more than 50 types of cancers. More than 45 of them currently lack recommended screening tests, the firms noted.

Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide a diagnostic workup.

Study design for Grail MCED test presented at ASCO
Grail this week announced a presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago describing a study design...
Grail, AstraZeneca to collaborate on companion diagnostic tests
Grail on Thursday announced its strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s...
Grail collaborates with VA on Galleri study
Grail is collaborating with the U.S. Department of Veterans Affairs (VA) Health Administration on a large-scale observational study assessing the performance...
Intermountain Healthcare to offer Galleri cancer blood test
Utah-based health system Intermountain Healthcare will be offering Grail’s Galleri multicancer early detection blood test as a complement to existing...
Grail to partner with Premier
Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's...

Copyright © 2022 LabPulse.com

Last Updated lo 6/23/2022 6:32:57 AM